HK Stock Market Move | LONGBIO-B(01779) rebounded over 7% after recently entering the Hong Kong Stock Connect list. The core pipeline product LP-003 BLA has been accepted for review.

date
10:37 08/09/2026
avatar
GMT Eight
Tianchen Biotech-B (01779) rebounded over 7%, after the stock fell more than 10% on its first day of trading yesterday.
LONGBIO-B (01779) rebounded more than 7%, after the stock fell over 10% on its first day of entry into the Hong Kong Stock Connect yesterday. As of the time of writing, it rose 7.06%, priced at HKD 122.9, with a trading volume of HKD 14.01 million. On the news front, starting from September 7, Tianchen Biotech officially entered the Hong Kong Stock Connect list. The company previously stated that if it is smoothly included in the Stock Connect, it will further broaden the investor base, enhance stock trading liquidity, and optimize the shareholder structure, providing strong support for pipeline research and development, industrial cooperation, and the companys long-term development. It is worth mentioning that in August of this year, the company's self-developed new anti-IgE antibody LP-003's Biologics License Application (BLA) targeting seasonal allergic rhinitis has officially been accepted by the National Medical Products Administration (NMPA), marking a key step towards the commercialization of this next-generation anti-IgE antibody.